Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Your search for ESKD returned 3 results
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.